ATE536867T1 - Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen - Google Patents

Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen

Info

Publication number
ATE536867T1
ATE536867T1 AT07753217T AT07753217T ATE536867T1 AT E536867 T1 ATE536867 T1 AT E536867T1 AT 07753217 T AT07753217 T AT 07753217T AT 07753217 T AT07753217 T AT 07753217T AT E536867 T1 ATE536867 T1 AT E536867T1
Authority
AT
Austria
Prior art keywords
exchange resin
ion exchange
release formulations
modified release
drug
Prior art date
Application number
AT07753217T
Other languages
English (en)
Inventor
Ketan Mehta
Yu-Hsing Tu
Original Assignee
Tris Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536867(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tris Pharma Inc filed Critical Tris Pharma Inc
Application granted granted Critical
Publication of ATE536867T1 publication Critical patent/ATE536867T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
AT07753217T 2006-03-16 2007-03-15 Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen ATE536867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78318106P 2006-03-16 2006-03-16
PCT/US2007/006572 WO2007109104A2 (en) 2006-03-16 2007-03-15 Modified release formulations containing drug-ion exchange resin complexes

Publications (1)

Publication Number Publication Date
ATE536867T1 true ATE536867T1 (de) 2011-12-15

Family

ID=38512117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07753217T ATE536867T1 (de) 2006-03-16 2007-03-15 Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen

Country Status (14)

Country Link
US (23) US8062667B2 (de)
EP (2) EP2428205B1 (de)
JP (1) JP5479086B2 (de)
KR (1) KR101495146B1 (de)
CN (2) CN102488652B (de)
AT (1) ATE536867T1 (de)
BR (1) BRPI0709606B8 (de)
CA (1) CA2645855C (de)
DK (2) DK2018160T3 (de)
ES (2) ES2396039T3 (de)
IL (1) IL194042A (de)
RU (1) RU2435569C2 (de)
TW (1) TW200812649A (de)
WO (1) WO2007109104A2 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2301526B1 (de) 2003-03-26 2016-03-23 Egalet Ltd. System zur kontrollierten Freisetzung von Morphin
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
WO2008042218A1 (en) * 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
EP2150242A2 (de) * 2007-04-20 2010-02-10 Wockhardt Research Centre Pharmazeutische zusammensetzungen von duloxetin
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
WO2009130715A1 (en) * 2008-04-25 2009-10-29 Cadila Healtcare Limited Rapidly disintegrating oral compositions of tramadol
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US20100280059A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
CA2760688A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US9211292B2 (en) * 2010-04-21 2015-12-15 Alitair Pharmaceuticals Inc Preventing or reducing drug abuse and overdose events
US8617602B2 (en) * 2010-09-03 2013-12-31 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
US8623409B1 (en) * 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US8287903B2 (en) * 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
BR112013020537B1 (pt) * 2011-02-15 2021-09-08 Tris Pharma, Inc Suspensão oral e mescla de pó de liberação prolongada aquosa de metilfenidato, método para fornecer um produto em suspensão líquida de metilfenidato, e formulação
EP2726066B1 (de) * 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosisformen für amphetamin zur oralen verabreichung
US20140127300A1 (en) * 2011-06-30 2014-05-08 Neos Therapeutics, Lp Abuse resistant drug forms
US20130105399A1 (en) * 2011-11-02 2013-05-02 University Of Illinois Urbana Champaign Polymer-encapsulated liquid exchange media
US20150056288A1 (en) * 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
WO2013119231A1 (en) * 2012-02-09 2013-08-15 Tris Pharma, Inc. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
WO2013164121A1 (en) 2012-05-02 2013-11-07 Capsugel France SAS Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
CN102885791B (zh) * 2012-09-24 2015-03-04 浙江万晟药业有限公司 一种制备盐酸非索非那定口腔崩解片的方法
EP3446685A1 (de) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
MX2015008171A (es) * 2012-12-20 2015-09-16 Synthon Bv Formulacion que comprende agomelatina amorfa.
EP2749309B1 (de) 2012-12-28 2016-04-27 Cook Medical Technologies LLC Ionenaustauschharnröhrenstent
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
JP6516720B2 (ja) 2013-03-13 2019-05-22 トリス・フアルマ・インコーポレーテツド ベンゾナテート改変放出性固体錠剤およびカプセル剤
US10420729B2 (en) * 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
US9782516B2 (en) * 2013-03-15 2017-10-10 Abbott Cardiovascular Systems Inc. Tissue adhesive coatings for drug coated balloon
US20140271891A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
US20140271893A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015037019A2 (en) * 2013-09-15 2015-03-19 Rubicon Research Private Limited Modified release pharmaceutical formulations
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
WO2015076821A1 (en) * 2013-11-22 2015-05-28 Tris Pharma, Inc. Novel clonidine formulation
EP2875817B1 (de) * 2013-11-26 2020-03-18 Synhton B.V. Pharmazeutische Formulierung enthaltend amorphes Lenalidomid
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
CN103860464B (zh) * 2014-03-19 2016-03-16 广州帝奇医药技术有限公司 一种抗过敏药物缓释混悬剂及其制备方法
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
ES2908142T3 (es) * 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
US20170128379A1 (en) * 2014-06-30 2017-05-11 Rubicon Research Private Limited Modified release pharmaceutical preparations
MX2017000041A (es) 2014-07-03 2017-05-01 Mallinckrodt Llc Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
EP4134070A1 (de) * 2014-07-17 2023-02-15 Pharmathen S.A. Pädiatrisches pulver zur oralen suspension mit antiviralem wirkstoff und verfahren zur herstellung davon
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
CN104628587B (zh) * 2015-02-12 2016-06-22 艾美科健（中国）生物医药有限公司 一种回收阿莫西林生产废液中d-对羟基苯甘氨酸的方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3288539A4 (de) * 2015-05-01 2019-07-10 Sun Pharmaceutical Industries Ltd Flüssige retard-zusammensetzungen von metformin
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US10358894B2 (en) * 2015-12-11 2019-07-23 Dreco Energy Services Ulc System for placing a tracer in a well
CN105663038B (zh) * 2016-02-03 2019-06-14 北京诺康达医药科技股份有限公司 一种液体缓释制剂及其制备方法
US11938224B1 (en) 2016-04-08 2024-03-26 Tris Pharma Inc Benzonatate modified release solid tablets and capsules
DK3445344T3 (da) 2016-04-21 2020-11-23 Fertin Pharma As Nikotinadministrationsprodukt, relaterede anvendelser og orale doseringsformer, samt fremgangsmåder til fremstilling
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
CA3022933A1 (en) * 2016-05-03 2017-11-09 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
WO2018071381A1 (en) 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
GB2555442B (en) * 2016-10-27 2022-06-01 Oxford Pharmascience Ltd Modifier system for compositions containing layered double hydroxide
CN106344522B (zh) * 2016-11-11 2019-04-09 河北利华药业有限公司 一种兽用阿莫西林颗粒及其制备方法
US9855228B1 (en) * 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof
CN106632804A (zh) * 2016-12-31 2017-05-10 重庆文理学院 绿色阳离子交换树脂制备方法
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019032975A1 (en) * 2017-08-10 2019-02-14 Mec Device Pharma International Llc ANTI-ABUSE MEDICINAL FORMULATIONS
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
JP2020536892A (ja) * 2017-10-09 2020-12-17 ローズ ファーマシューティカルズ エル．ピー． 医薬レジネート組成物、それを作製する方法、およびその使用
GR1009534B (el) * 2017-11-21 2019-05-31 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη οξυβουτυνινη
CN108030770A (zh) * 2017-12-18 2018-05-15 中国药科大学 含有药物树脂复合物的释药可控的干混悬剂及其制备方法
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CN108014120A (zh) * 2017-12-18 2018-05-11 中国药科大学 一种释药速度可控的阿奇霉素树脂复合物及其掩味干混悬剂
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
KR20200117999A (ko) * 2017-12-22 2020-10-14 디디피 스페셜티 일렉트로닉 머티리얼즈 유에스 8 엘엘씨 수지 입자를 함유하는 약학적 조성물
FR3079303A1 (fr) 2018-03-20 2019-09-27 Ab7 Innovation Procede pour la detection de la presence d'un traceur dans les excrements
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
US20220241222A1 (en) * 2019-06-26 2022-08-04 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
WO2021071902A1 (en) * 2019-10-10 2021-04-15 Brillian Pharma Inc. Micronized drug resinate-based pharmaceutical compositions and methods of preparation thereof
US20230158160A1 (en) * 2020-05-23 2023-05-25 Lyrus Life Sciences Pvt. Ltd. Pharmaceutical composition of extended-release oral suspension and process for preparation thereof
CN111617032A (zh) * 2020-07-08 2020-09-04 江苏四环生物制药有限公司 一种布洛芬药物纤维混悬剂及其制备方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
CN112362765B (zh) * 2020-10-13 2022-06-17 长沙都正生物科技股份有限公司 一种多塞平及其代谢产物n-去甲多塞平固相萃取、检测方法及试剂盒
CN114088680B (zh) * 2021-10-14 2023-06-27 安徽中科赛飞尔科技有限公司 一种染发样品中痕量毒品的快速检测方法
WO2023147443A2 (en) * 2022-01-26 2023-08-03 Tulex Pharmaceuticals Inc. Novel compositions
CN115350152A (zh) * 2022-07-27 2022-11-18 武汉科福新药有限责任公司 一种普萘洛尔缓释口服混悬液及其制备方法
WO2024023785A1 (en) 2022-07-29 2024-02-01 Berlia Sushma Paul A stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US659463A (en) 1899-11-18 1900-10-09 E & A H Batcheller Company Heel-attaching machine.
US692988A (en) 1901-05-20 1902-02-11 Seneca Falls Mfg Company Drill-chuck.
US2099402A (en) 1934-01-17 1937-11-16 Pratt Food Company Pill or tablet
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2830933A (en) 1955-07-14 1958-04-15 Pfizer & Co C Vitamin b12 products and preparation thereof
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
US3146919A (en) 1960-10-17 1964-09-01 Story F Chappell Ball follower dispenser
US3138525A (en) 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3365365A (en) 1965-08-09 1968-01-23 Hoffmann La Roche Repeat action pharmaceutical compositions in the form of discrete beadlets
US3594470A (en) 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
GB1218102A (en) 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
US3567079A (en) 1968-08-08 1971-03-02 Cleone H Weigand Dispenser container with metering neck
LU63060A1 (de) 1971-04-26 1971-08-26
DE2246037B2 (de) 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform
DE2322883A1 (de) 1973-05-07 1974-11-28 Roehm Gmbh Wasserloesliche polymerisate
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4363323A (en) 1980-12-04 1982-12-14 Geiss Alan C Nasogastric tube adapted to avoid pressure necrosis
JPS5941574U (ja) 1982-09-07 1984-03-17 三菱鉛筆株式会社 ボ−ルペン
CH655507B (de) * 1983-01-12 1986-04-30
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4762709A (en) 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4876094A (en) * 1984-01-13 1989-10-24 Battelle Development Corporation Controlled release liquid dosage formulation
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4847077A (en) 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4600645A (en) 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
US4619673A (en) 1985-05-15 1986-10-28 Multiform Desiccants, Inc. Adsorbent device
WO1987000044A1 (en) 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPS62103012A (ja) 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
DE3617432A1 (de) 1986-05-23 1987-11-26 Standard Elektrik Lorenz Ag Elektronenstrahlerzeugungssystem
US4859461A (en) 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
GB2201395B (en) 1986-12-17 1990-05-02 English Glass Co Ltd Liquid dosing device
US4910932A (en) 1987-01-05 1990-03-27 Honigman Michael L Modular building system
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US4808411A (en) 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
IL90245A (en) 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
JPH01287270A (ja) 1988-05-13 1989-11-17 Matsushita Electric Ind Co Ltd スパッタリング装置
JPH0217912A (ja) 1988-07-06 1990-01-22 Matsushita Electric Ind Co Ltd 空気清浄機
US5296236A (en) 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US4999189A (en) 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US5275819A (en) 1989-02-06 1994-01-04 Amer Particle Technologies Inc. Drug loaded pollen grains with an outer coating for pulsed delivery
HU207940B (en) 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
JP3126127B2 (ja) 1989-04-28 2001-01-22 アジレント・テクノロジー株式会社 試験データ圧縮方式
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5242428A (en) 1991-10-04 1993-09-07 Aubrey Palestrant Apparatus for wetting hydrophilic-coated guide wires and catheters
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
AU672772B2 (en) 1991-12-27 1996-10-17 Theta Biomedical Consulting & Development Co., Inc. Alleviating or prevention of migraine headache onset with mast cell degranulation blocking agents
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5322073A (en) 1992-01-30 1994-06-21 Sandoz Ltd. Feeding tube retaining strap
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
DE4319649A1 (de) 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
AU706541B2 (en) 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
DE69606713T2 (de) * 1995-08-29 2000-08-03 Exxon Chemical Patents Inc Strahlungsbeständiges polypropylen und daraus herstellbare gegenstände
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
JPH09323180A (ja) 1996-06-04 1997-12-16 Asahi Optical Co Ltd スケーリング補正機能を持つレーザ描画装置
DE69735581T2 (de) 1996-09-30 2007-01-25 Alza Corp., Palo Alto Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
CN1179450A (zh) * 1996-10-15 1998-04-22 罗姆和哈斯公司 含有离子交换树脂的涂料组合物
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5900882A (en) 1996-11-15 1999-05-04 Samsung Electronics Co., Ltd. Determining texture coordinates in computer graphics
PT946145E (pt) * 1996-12-20 2008-10-17 Mcneil Ppc Inc Fármacos antitússicos libertados por resinas de troca iónica
DE19709663A1 (de) 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
DE19709532A1 (de) 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
JP2001526229A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド投薬剤形の乱用を防止する方法
EP0943341A1 (de) 1998-02-18 1999-09-22 Oscar Gold Verfahren zur Herstellung von Erythromycin Macrolide enthaltenden Granulaten und Arzneimitteln
IT1304271B1 (it) 1998-03-17 2001-03-13 Tecno 5 S R L Gruppo serigrafico polifunzionale per macchine a giostra per la stampa serigrafica a piu' colori di contenitori con superfici curve.
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20070160675A1 (en) 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
CZ303495B6 (cs) 1998-11-02 2012-10-24 Elan Pharma International Limited Mnohocásticový modifikovane uvolnující prostredek a jeho použití, pevná orální dávkovací forma
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
WO2000040224A1 (en) * 1999-01-07 2000-07-13 Elan Corporation, Plc Multiparticulate oral dosage forms
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2366791A1 (en) 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
DE19927689A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
JP2003522127A (ja) 1999-07-29 2003-07-22 ロクセニ ラボラトリーズ インコーポレイテッド オピオイド徐放性製剤
DE19961897A1 (de) 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
DK1248594T3 (da) 2000-01-19 2006-02-06 Mannkind Corp Formulering med multi-spidsfrigivelse til indgivelse af lægemidler
EP2092936B1 (de) 2000-02-08 2013-03-20 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US6322011B1 (en) 2000-03-14 2001-11-27 Illinois Tool Works Inc. Electrostatic coating system and dual lip bell cup therefor
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6670058B2 (en) 2000-04-05 2003-12-30 University Of Central Florida Thermocatalytic process for CO2-free production of hydrogen and carbon from hydrocarbons
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
JP3380536B2 (ja) 2000-08-25 2003-02-24 日本圧着端子製造株式会社 圧接コネクタの受取装置及びこれを備えた自動圧接機
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
GB0030460D0 (en) 2000-12-14 2001-01-24 Isis Innovation Drug delivery system
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
ATE330586T1 (de) 2001-03-14 2006-07-15 Pfizer Prod Inc Pharmazeutische tablette und eine verfahren zu deren herstellung
EP1250937B1 (de) 2001-04-09 2009-05-13 Rohm And Haas Company Kontrollierte Auflösung von Wirkstoffen
WO2002092059A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
EP1277896A1 (de) 2001-07-16 2003-01-22 Ulf Palmberg Fussbodenplatten
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
EP1429728A1 (de) 2001-08-29 2004-06-23 SRL Technologies, Inc. Zubereitungen mit verzögerter freisetzung
EP1425557A1 (de) 2001-09-12 2004-06-09 Anthony Charles Lammond Wass Verbesserte dosiervorrichtung
CN100562317C (zh) 2001-10-17 2009-11-25 武田药品工业株式会社 含大量酸不稳定药物的颗粒
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US6939029B1 (en) 2002-05-28 2005-09-06 Kuryakyn Holdings, Inc. Modular light assembly for decorative lights
MXPA04011646A (es) 2002-06-05 2005-03-07 Baylor College Medicine Secuencias cdr3 de receptor de celula t y metodos para deteccion.
CA2499465A1 (en) 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
JP2006500395A (ja) 2002-09-09 2006-01-05 エンド ファーマシューティカルズ インコーポレーテッド 組み合わされた即時放出及び徐放の鎮痛組成物
CA2500026A1 (en) 2002-09-24 2004-04-08 Gumlink A/S Chewing gum having improved release of chewing gum ingredients
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
AU2003297561A1 (en) 2002-11-26 2004-06-18 Garry R. Hollenbeck Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US20060018972A1 (en) 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
FR2848564B1 (fr) * 2002-12-13 2006-12-01 Inst Rech Developpement Ird Souches bacteriennes du genre exiguobacterium, procede de culture et applications
US20070036851A1 (en) * 2002-12-23 2007-02-15 Deepak Thassu Acid labile drug compositions
US8110223B2 (en) * 2002-12-31 2012-02-07 University Of Maryland, Baltimore Methods for making pharmaceutical dosage forms containing active cushioning components
US6780126B2 (en) * 2003-01-02 2004-08-24 Acushnet Company Golf ball with large inner core
EP1592453A1 (de) 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate aufbau von milnacipran für orale einnahme
CH712083B1 (de) 2003-02-05 2017-07-31 Siegfried Ag Verfahren zur Herstellung von d-threo-2-Phenyl-2-piperidin-2-yl-essigsäureestern.
AU2004210671A1 (en) 2003-02-10 2004-08-26 Shire Canada Inc. Enantiomeric amphetamine compositions for the treatment of ADHD
US20060115529A1 (en) * 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
EP1636091A2 (de) 2003-05-12 2006-03-22 Medical Instill Technologies, Inc. Abgabevorrichtung und vorrichtung zum füllen einer abgabevorrichtung
US20040259809A1 (en) 2003-06-17 2004-12-23 Pediamed Pharmaceuticals, Inc. Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof
US20050036977A1 (en) 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
WO2005023217A2 (en) 2003-09-03 2005-03-17 Mallinckrodt Inc. Granular sustained release preparation and production thereof
US7691880B2 (en) 2003-10-08 2010-04-06 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
WO2005034999A2 (en) 2003-10-10 2005-04-21 Bvm Holding Co. Composition comprising association complex of a pharmaceutical and a poloxamer
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232987A1 (en) 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20060029664A1 (en) 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US20050232986A1 (en) 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20050142097A1 (en) 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20050181050A1 (en) 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
JP2005306778A (ja) 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20050265955A1 (en) 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US9592197B2 (en) 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
AU2005276554B2 (en) 2004-08-23 2011-08-25 Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co. Kg Psychostimulant containing pharmaceutical composition
CA2581002C (en) 2004-10-15 2012-01-10 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
US7173497B1 (en) 2004-11-05 2007-02-06 Rockwell Collins, Inc. Sampling voltage controlled oscillator
EP1830851A2 (de) 2004-12-06 2007-09-12 Themis Laboratories Private Limited Schnell auflösende zusammensetzung mit maskiertem geschmack und herstellungsverfahren dafür
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7276794B2 (en) 2005-03-02 2007-10-02 Endevco Corporation Junction-isolated vias
EP1893175A1 (de) 2005-06-09 2008-03-05 Upm Pharmaceuticals, Inc. Wässriges arzneistoffabgabesystem mit anhaltender wirkstofffreigabe für stark wasserlösliche elektrolytika
JP2008546835A (ja) 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体
AU2006263338A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
WO2007100777A2 (en) 2006-02-28 2007-09-07 The Mclean Hospital Corporation Methods for the treatment of adhd and related disorders
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20080064694A1 (en) 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008042218A1 (en) 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
US20080118570A1 (en) 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
CA2669410C (en) 2006-11-21 2015-07-14 Mcneil-Ppc, Inc. Modified release analgesic suspensions
BRPI0720105A2 (pt) 2006-12-11 2014-10-07 Kempharm Inc Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
WO2008103538A1 (en) 2007-02-21 2008-08-28 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
JP2010529040A (ja) 2007-05-30 2010-08-26 ネオス・セラピューティクス・エルピー イオン性樹脂系の懸濁液における薬物放出の調節
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
JP5279246B2 (ja) 2007-12-05 2013-09-04 京セラドキュメントソリューションズ株式会社 画像形成装置および印刷システム
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2376451A1 (de) 2009-01-09 2011-10-19 Mallinckrodt LLC Methylphenidatsynthese und analoga daraus
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
GB201002612D0 (en) 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
JP2013523651A (ja) 2010-03-24 2013-06-17 ノースイースタン ユニヴァーシティ 多重コンパートメントのマクロファージ送達
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
BR112013020537B1 (pt) 2011-02-15 2021-09-08 Tris Pharma, Inc Suspensão oral e mescla de pó de liberação prolongada aquosa de metilfenidato, método para fornecer um produto em suspensão líquida de metilfenidato, e formulação
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2726066B1 (de) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosisformen für amphetamin zur oralen verabreichung
JP5926377B2 (ja) 2011-07-01 2016-05-25 ドルビー ラボラトリーズ ライセンシング コーポレイション サンプルレートスケーラブル可逆オーディオコーディング
CA2758556A1 (en) 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
WO2014058742A1 (en) 2012-10-09 2014-04-17 Sears Douglas Therapeutic treatment
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
US20100166858A1 (en) 2010-07-01
JP5479086B2 (ja) 2014-04-23
US20160310438A1 (en) 2016-10-27
CN101400343A (zh) 2009-04-01
ES2396039T3 (es) 2013-02-18
WO2007109104A3 (en) 2007-12-13
US20130136797A1 (en) 2013-05-30
DK2428205T3 (da) 2012-10-22
BRPI0709606A2 (pt) 2011-07-19
US10172958B2 (en) 2019-01-08
US9198864B2 (en) 2015-12-01
US20140127306A1 (en) 2014-05-08
KR20080108520A (ko) 2008-12-15
US8337890B2 (en) 2012-12-25
KR101495146B1 (ko) 2015-02-24
US8747902B2 (en) 2014-06-10
EP2428205A1 (de) 2012-03-14
EP2428205B1 (de) 2012-10-03
US20210038734A1 (en) 2021-02-11
US20150272893A1 (en) 2015-10-01
US20190151460A1 (en) 2019-05-23
US20200121797A1 (en) 2020-04-23
US20160158373A1 (en) 2016-06-09
US8790700B2 (en) 2014-07-29
BRPI0709606B1 (pt) 2020-04-22
US20220168432A1 (en) 2022-06-02
DK2018160T3 (da) 2012-02-06
US20170274088A1 (en) 2017-09-28
US8597684B2 (en) 2013-12-03
TW200812649A (en) 2008-03-16
AU2007227569B2 (en) 2013-09-12
US20140056984A1 (en) 2014-02-27
CN102488652A (zh) 2012-06-13
AU2007227569A1 (en) 2007-09-27
US9522191B2 (en) 2016-12-20
US20150024059A1 (en) 2015-01-22
US8883217B2 (en) 2014-11-11
US20120015030A1 (en) 2012-01-19
US10086087B2 (en) 2018-10-02
US8202537B2 (en) 2012-06-19
US9549989B2 (en) 2017-01-24
JP2009530298A (ja) 2009-08-27
RU2008140944A (ru) 2010-04-27
US20190142952A1 (en) 2019-05-16
ES2378573T3 (es) 2012-04-16
US20130059007A1 (en) 2013-03-07
US8491935B2 (en) 2013-07-23
WO2007109104A2 (en) 2007-09-27
BRPI0709606B8 (pt) 2021-05-25
US20170100487A1 (en) 2017-04-13
US10933143B2 (en) 2021-03-02
US20140030334A1 (en) 2014-01-30
IL194042A0 (en) 2009-08-03
CN102488652B (zh) 2014-06-18
US10668163B2 (en) 2020-06-02
EP2018160B1 (de) 2011-12-14
RU2435569C2 (ru) 2011-12-10
CN101400343B (zh) 2012-01-11
CA2645855C (en) 2015-02-03
IL194042A (en) 2014-06-30
US20180000954A1 (en) 2018-01-04
US20070215511A1 (en) 2007-09-20
US9675704B2 (en) 2017-06-13
US20160310478A1 (en) 2016-10-27
US20210162055A1 (en) 2021-06-03
CA2645855A1 (en) 2007-09-27
US9675703B2 (en) 2017-06-13
US20160310449A1 (en) 2016-10-27
US8062667B2 (en) 2011-11-22
EP2018160A2 (de) 2009-01-28

Similar Documents

Publication Publication Date Title
ATE536867T1 (de) Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
WO2008064163A3 (en) Polymer coated drug-ion exchange resins and methods
JP2009522296A5 (de)
DE602007005653D1 (de) Mehrschichtige im mund zerfallende tablette
RS52891B (en) GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
MX2009004789A (es) Nucleos de liberacion de sabor y su uso en goma de mascar.
DE602006004610D1 (de) Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung
WO2012063257A3 (en) Sustained release compositions
MX2011010324A (es) Tableta recubierta que se desintegra oralmente.
DE60304904D1 (de) Verfahren zur herstellung vonmedizinprodukten mit antimikrobiellen beschichtungen
WO2007109244A3 (en) Novel nanoparticles for delivery of active agents
WO2008059375A3 (en) Moist tobacco product and method of making
JP2006305390A5 (de)
WO2007109057A3 (en) Solid dosage form containing a taste masked active agent
WO2009006218A3 (en) Personal care dissolvable films
DE60022332D1 (de) Ketoprofen mikrogranulat, verfahren zur herstellung desselben sowie pharmazeutische zusammensetzungen
JO2801B1 (en) A pharmaceutical preparation for oral use has the ability to control the release of an active ingredient in the small intestine and the way it is manufactured
DE602006000819D1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
WO2009149058A8 (en) Modified release niacin formulations
WO2012092486A3 (en) Modified release benzimidazole formulations
AU2003218724A8 (en) Film coatings with controlled release and high stability
WO2012104641A3 (en) Pharmaceutical formulation
ATE448067T1 (de) Verfahren zur herstellung eines beschichteten thermoplastmaterials
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
WO2009087663A3 (en) Oral controlled release coated tablet